I. López

发表

Differential tumor expression of inhibitor of differentiation-1 in prostate cancer patients with extreme clinical phenotypes and prognostic implications.

M. Ponz-Sarvisé, E. Castañón, Á. Panizo-Santos, 2014, Clinical genitourinary cancer.

The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment of the pre-metastatic niche.

C. Rolfo, L. Raez, E. Castañón, 2017, Cancer letters.

Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis

C. Rolfo, E. Castañón, I. López, 2015, Journal of Translational Medicine.

Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells

S. Vicent, C. Rolfo, J. Lasarte, 2020, Cancers.

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target

S. Vicent, C. Rolfo, I. López, 2018, Molecular Cancer.

The inhibitor of differentiation isoform Id1b, generated by alternative splicing, maintains cell quiescence and confers self-renewal and cancer stem cell-like properties.

I. López, A. Calvo, P. Nguewa, 2015, Cancer letters.

Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy

J. Bosch-Barrera, E. Castañón, I. López, 2013, Journal of Translational Medicine.

Safety and efficacy of maintenance therapy with a nonspecific cytochrome P17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer.

E. Castañón, I. López, I. Gil-Aldea, 2013, Clinical genitourinary cancer.

Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis

C. Rolfo, E. Castañón, I. López, 2015, Journal of Translational Medicine.

Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network.

I. Wistuba, S. Vicent, C. Behrens, 2018, Cancer research.

The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer

S. Vicent, É. Darbo, F. Lecanda, 2023, Molecular Cancer.

Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed

M. Rodriguez-Ruiz, A. Patiño-García, C. Rolfo, 2014, Journal of Translational Medicine.

The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer

S. Vicent, É. Darbo, F. Lecanda, 2023, Molecular Cancer.

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target

S. Vicent, C. Rolfo, I. López, 2018, Molecular Cancer.

The inhibitor of differentiation isoform Id1b, generated by alternative splicing, maintains cell quiescence and confers self-renewal and cancer stem cell-like properties.

I. López, A. Calvo, P. Nguewa, 2015, Cancer Letters.

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

P. Khatri, F. Lecanda, M. Drosten, 2023, Nature communications.

A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer

I. López, I. Peñuelas, M. Ecay, 2023, Frontiers in immunology.